Impact of the duration of oestradiol treatment on live birth rate in Hormonal Replacement Therapy cycle before frozen blastocyst transfer.

Hormonal replacement treatment cycle IVF blastocyst frozen embryo transfer live birth rate

Journal

Human fertility (Cambridge, England)
ISSN: 1742-8149
Titre abrégé: Hum Fertil (Camb)
Pays: England
ID NLM: 100888143

Informations de publication

Date de publication:
03 Jan 2023
Historique:
entrez: 3 1 2023
pubmed: 4 1 2023
medline: 4 1 2023
Statut: aheadofprint

Résumé

Although the duration of progesterone administration in Hormonal Replacement Therapy (HRT) cycles before frozen embryo transfer is standardized, the optimal duration of oestrogen treatment remains controversial. In this monocentric retrospective study conducted in all single frozen blastocyst transfer (FBT) performed with HRT between January 2016 and July 2019, we evaluated the association between the duration of oestradiol treatment before FBT and live birth rate (LBR) in HRT cycles. Cycles were gathered in 3 groups according to quartiles of duration of oestrogen treatment. LBR was compared across the 3 groups and multivariate analysis was performed. We included 2235 single FBT cycles; 507, 1257 and 471 with E2 treatment below 23 days, 23-30 days (reference) and more than 30 days respectively. After multivariate analysis and adjustment, no significant difference in LBR was found between below 23 or more than 30 days and reference groups (OR = 0.93 [0.68-1.27] and OR = 1.29 [0.88-1.89] respectively). Complementary sensitivity analysis led to a non-significant adjusted OR = 1.66 [IC 0.9-3.1]. In conclusion, our study showed that the duration of E2 treatment in HRT cycles before FBT is not associated with LBR.

Identifiants

pubmed: 36594497
doi: 10.1080/14647273.2022.2163467
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Auteurs

Juliette Joly (J)

Service de Médecine et Biologie de la Reproduction, Hôpital Mère et Enfant, CHU de Nantes, Nantes, France.

Thomas Goronflot (T)

INSERM, University Hospital of Nantes, Nantes, France.

Arnaud Reignier (A)

Service de Médecine et Biologie de la Reproduction, Hôpital Mère et Enfant, CHU de Nantes, Nantes, France.
Faculté de Médecine, Nantes, France.
Centre de Recherche en Transplantation et Immunologie, Inserm, Université de Nantes, Nantes, France.

Martin Rosselot (M)

Service de Médecine et Biologie de la Reproduction, Hôpital Mère et Enfant, CHU de Nantes, Nantes, France.

Florence Leperlier (F)

Service de Médecine et Biologie de la Reproduction, Hôpital Mère et Enfant, CHU de Nantes, Nantes, France.

Paul Barrière (P)

Service de Médecine et Biologie de la Reproduction, Hôpital Mère et Enfant, CHU de Nantes, Nantes, France.
Faculté de Médecine, Nantes, France.

Pierre-Antoine Gourraud (PA)

INSERM, University Hospital of Nantes, Nantes, France.
Faculté de Médecine, Nantes, France.
Centre de Recherche en Transplantation et Immunologie, Inserm, Université de Nantes, Nantes, France.

Thomas Fréour (T)

Service de Médecine et Biologie de la Reproduction, Hôpital Mère et Enfant, CHU de Nantes, Nantes, France.
Faculté de Médecine, Nantes, France.
Centre de Recherche en Transplantation et Immunologie, Inserm, Université de Nantes, Nantes, France.
Department of reproductive Medicine, Dexeus University Hospital, Barcelona, Spain.

Tiphaine Lefebvre (T)

Service de Médecine et Biologie de la Reproduction, Hôpital Mère et Enfant, CHU de Nantes, Nantes, France.
Faculté de Médecine, Nantes, France.

Classifications MeSH